Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia parecoxib

Executive Summary

Pharmacia will submit additional data to FDA in 12 to 18 months following July 13 "not approvable" letter for its injectable COX-2 inhibitor parecoxib. The letter "indicated that there were deficiencies in the application," and requested confirmatory data, Pharmacia said. The application was filed in September 2000
Advertisement

Related Content

Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”
Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”
Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug
Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug
Advertisement
UsernamePublicRestriction

Register

PS038188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel